Brepocitinib 30 mg improved Total Improvement Score versus placebo in dermatomyositis patients over 52 weeks
New Pill Eases Stubborn Muscle and Skin Disease Symptoms
This Phase 3, double-blind, randomized, placebo-controlled trial enrolled 241 adults with dermatomyositis. The once-daily oral brepocitinib …
• Brepocitinib 30 mg significantly improves muscle strength and skin rashes • Helps adults with treatment-resistant dermatomyositis regain d…
Male sex and advanced age associated with higher risk of RP-ILD in anti-MDA5 dermatomyositis patients
Some Patients With This Rare Lung-Muscle Disease Face Faster Decline
This systematic review and meta-analysis of 15 studies evaluated factors associated with rapidly progressive interstitial lung disease (RP-I…
Men and older adults with a rare autoimmune lung disease are at higher risk of rapid, life-threatening lung damage, a new review finds.
Mendelian randomization suggests potential causal link between severe COVID-19 and polymyositis risk
Severe COVID-19 May Set Off a Rare Muscle Disease, Genetic Study Hints
A single-center cohort study of 108 hospitalized COVID-19 patients used Mendelian randomization to explore associations with polymyositis.
A new genetic analysis adds to growing concern that severe COVID-19 can quietly trigger immune attacks on healthy muscle months later.
JSLE linked to higher CVD risk factors than JDM in adults with childhood-onset autoimmune diseases
Study compares heart health risks in adults with childhood-onset lupus or dermatomyositis
A single-centre longitudinal cohort study of 76 JSLE and 79 JDM adults found JSLE had higher hypertension, dyslipidaemia, and cholesterol le…
Adults with childhood lupus face higher heart risks like high blood pressure and cholesterol compared to those with juvenile dermatomyositis…